Commercializing Gene Therapies: Building Your Strategy From Translation Through to Commercial

19 Jan 2023
Commercializing the Therapies of the Future Track
Fujifilm Diosynth Biotechnologies

Chair Introduction

Serene Forte, Senior Vice President, Head of Genetic Medicine, RELIEF Therapeutics

11:05am Presentation: Lost in Translation: Anticipating Hurdles to Expedite the Transition to Commercialization

Discover how to design a customized and innovative strategy to overcome every barrier on the commercialization journey

  • Supply chain hurdles from pre-clinical to commercial
  • Market access challenges
  • Patient support: how to design unique programs that meet patient needs

Lung-I Cheng, Vice President, Cell & Gene Therapy, AmerisourceBergen


11:20am Presentation: Key Learnings from Pathology Studies in Muscle Gene Therapy

  • Discuss the process of identifying treatment relevant tissue endpoints when translating pre-clinical studies to the human clinical trial stage
  • How can we use those endpoints to make assessments of efficacy in animal and human studies, and how well do animals predict human responses
  • What have our animal-to-human translations taught us about factors impacting efficacy, particularly issues that are unrelated to manufacturing (such as age at treatment or the time of biopsy following treatment)

Michael Lawlor, Professor of Pathology, Medical College of Wisconsin


11:35am Presentation: Integrated Solutions for Global Viral Vector Manufacturing

  • Summarizing viral vector experiences focusing on select challenges presented from various viral vectors
  • Opportunities for external manufacturers and biotech companies to merge ideas, development and manufacturing approaches
  • Integrating single-use manufacturing strategies within a global network

Ian Goodwin, Director, Global Program Design, FUJIFILM Diosynth Biotechnologies


11:05am Closing Panel with Q&A

With all session participants, joined by:

Lisa Deschamps, Chief Executive Officer, AviadoBio

Emily Chee, General Manager, Americas, Novartis Gene Therapies


Emily Chee
General Manager, Americas
Ian Goodwin
Director, Global Program Design,
Fujifilm Diosynth Biotechnologies
Lisa Deschamps
Chief Executive Officer
Lung-I Cheng
Vice President, Cell and Gene Therapy
Michael Lawlor
Medical College of Wisconsin
Serene Forte
Senior Vice President and Head of Genetic Medicine
RELIEF Therapeutics